The Canadian Government is funding studies to establish ketamine as a safe and effective treatment for patients with bipolar depression.
List view / Grid view
Here, Dr Matthew McMurray and Dr J Andrew Jones of Miami University explain why psychedelic drugs are attracting R&D as potential treatments for neuropsychiatric and degenerative disorders and how their discovery of an in vivo production technique could enable further advancement.
Side effects revealed during post-marketing experience are not listed on Atrolak XL prolonged-release tablet patient information leaflets, announces the MHRA.
Due to cross-contamination with enalapril maleate, Taro is voluntarily recalling one lot of its lamotrigine tablets at the consumer level.
The FDA has approved the first drug in the U.S. with a digital ingestion tracking system that records that the medication was taken...
Genes linked to schizophrenia in psychiatric patients suffering from bipolar disorder are the reason why such patients don't respond to the drug lithium...